# Curve Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/curve-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Southampton, UK
- Website: www.curvetx.com
- Total disclosed funding: $55M
- Latest round: Series A (Feb 27, 2024)
- Investors on record: 5

## About

Established in 2019 and based in Southampton, UK, Curve Therapeutics Limited operates as a biotechnology research company that uses a Microcyle platform to build therapeutics that target protein-protein interactions for cancer treatment. The company was co-founded by Ali Tavassoli and Simon Kerry, Ph.D. In July 2020, Curve Therapeutics Limited raised GBP 1.25 million in series A venture funding from Investor Epidarex Capital. 

The company’s platform allows the identification of novel treatments by enabling functional screening against difficult targets in their natural cellular milieu. The Microcycle platform enables direct screening for biologically active hits and develops a toolset for a hit-to-lead program. The goal of the company is to allow functional screening against intractable targets in their native cellular environment to improve the discovery of new therapeutics.

## Funding rounds

- Series A, Feb 27, 2024, $51M — British Business Bank, Epidarex Capital, Pfizer Venture Investments, Advent Life Sciences, Columbus Venture Partners
- Series A, Jul 31, 2020, $1.6M — Epidarex Capital
- Series A, Jun 27, 2019, $1.6M — Advent Life Sciences

## Investors

- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Series A
- Epidarex Capital (https://capitalatlas.ai/funds/epidarex-capital) — Series A
- British Business Bank (https://capitalatlas.ai/funds/british-business-bank) — Series A
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series A
- Columbus Venture Partners (https://capitalatlas.ai/funds/columbus-venture-partners) — Series A